



October 20, 2009

PROTOCOL RTOG-0825

PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

NCI-Supplied Agent: Bevacizumab (NSC 704865; IND 7921)

Study Chair: Mark R. Gilbert, MD

STAGED CASE PAYMENT SCHEDULE

The case reimbursement for RTOG 0825 will be done in a series of staged payments according to the schedule below. Each payment will be triggered by the submission of the data form designated under Study Stage. All screen failures will receive Payment 1.

Payment	Study Stage	Payment Amount
1	2 nd Step Registration – A2	\$500
2	3 rd Step Registration – A3	\$1,500
3	1 st Treatment Summary Form – TF	\$2,000
4	1 st Follow Up Form – F1	\$1,000
5*	Neurocognitive Evaluation Baseline – CS	\$500
6*	Neurocognitive Evaluation Year 2 or Early Termination – CS	\$500

*These payments apply only to those cases for which informed consent has been obtained to participate in the QoL portion of the trial.

Maximum Potential Reimbursement:

\$6,000